Opinion|Videos|June 5, 2024
Clinical Impact of the Introduction of Disease-Modifying Treatments for Alzheimer Disease
Experts on Alzheimer disease discuss how the introduction of disease-modifying therapies has impacted the treatment landscape.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- What has been the clinical impact and the target patients for the use of anti-amyloid β monoclonal antibodies?
- Aducanumab approved by the FDA in 2021; development and commercialization discontinued on Jan 31, 2024
- Lecanemab approved by the FDA in 2023
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Novel Iberdomide Regimen in RRMM
2
CMS Final Rule Ends Federal Medicaid, CHIP Funding for Youth Gender-Affirming Care
3
Employers With Claims Data Access Take More Cost Action, Survey Finds
4
IL-17 Signaling Bridges Psoriasis and Cardiometabolic Risk, Review Finds
5